Atara Biotherapeutics GAAP EPS of $0.18 beats by $1.14, revenue of $51.58M beats by $45.05M

Aug. 08, 2022 4:19 PM ETAtara Biotherapeutics, Inc. (ATRA)By: Urvi Shah, SA News Editor
  • Atara Biotherapeutics press release (NASDAQ:ATRA): Q2 GAAP EPS of $0.18 beats by $1.14.
  • Revenue of $51.58M (+1232.8% Y/Y) beats by $45.05M.
  • Atara to Focus on R&D Activities Prioritizing Upcoming Milestones for Key Pipeline Assets

  • ATA188 Phase 2 EMBOLD Study Interim Analysis Completed with Target Enrollment Achieved; Primary Endpoint Data Read Out Planned for October 2023

  • FDA Recommended Pathway to Potential Tab-cel BLA Filing Without Need for New Clinical Trial; European Commission Approval on Track for Q4 2022

  • ATA3219 on Track for Q4 2022 IND Submission.

Recommended For You


To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.